Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angel Study
NCT03216902Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jul 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of sepetaprost in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Santen Pharmaceutical. Started Jul 2017; status: completed.
02
Drugs
sepetaprost
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT03216902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03216902.